Bellicum Pharms

BLCM NASDAQ
0.9900
-0.0100
-1.00%
Closed 17:00 08/16 EDT
Open
0.9640
Prev Close
1.000
High
1.050
Low
0.9100
Volume
2.44M
Avg Vol (3M)
666.85K
52 Week High
7.26
52 Week Low
0.9100
% Turnover
5.27%
Market Cap
45.79M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Bellicum Pharms BLCM stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
MORE >

Recently

Name
Price
%Change